Highest-materiality recent filing
Owlet shareholders approve 600k share plan increase; reelect two Class II directors
At Aug 12, 2026 annual meeting, stockholders approved Amendment No. 3 adding 600,000 shares to 2021 Incentive Award Plan.
Q2 revenue $33.9M vs $26.1M YoY; subscription revenue $3.2M vs $0.9M YoY.
Owlet secures $25M Wells Fargo credit facility, cuts borrowing cost by at least 525 bps
New $25M asset-based revolving credit facility with Wells Fargo, maturing June 2029.
Owlet postpones 2026 Annual Meeting to Aug 12 due to scheduling conflicts
Annual Meeting rescheduled from July 10 to August 12, 2026, at 1:00 p.m. ET via remote communication.
Owlet Q1 revenue $22.5M (+6.4% YoY); net loss $3.3M vs income $3.0M; cuts FY revenue guidance
Q1 revenue $22.5M (+6.4% YoY); subscription revenue record $2.7M; subscribers over 115k.
Owlet appoints Kurt Workman as President and CEO, succeeds Jonathan Harris
Kurt Workman appointed President and CEO effective April 6, 2026, succeeds Jonathan Harris.
Owlet reports record FY 2025 revenue of $105.7M, initiates 2026 guidance
Q4 2025 revenue $26.6M (+29.6% YoY); gross margin 47.6%; net loss $9.2M ($0.39/share).
Owlet derivative suit settlement hearing moved to Feb 25; governance reforms proposed
Hearing on settlement of Vargas v. Workman derivative action continued from Feb 6 to Feb 25, 2026.
Owlet reports record Q3 revenue $32M (+44.6%), net income $4.1M; raises FY25 guidance to $103-106M
Revenue $32.0M (record), up 44.6% YoY; gross margin 50.6% (down 150bps from tariffs).
Owlet prelim Q3 revenue $30-32M (up 36-45% YoY); gross margin 49.5-51%; launches $30M stock offering
Revenue for Q3 2025 estimated $30M-$32M vs $22.1M in Q3 2024 (approx. 36-45% YoY growth).
Stockholders approved issuance of 5,426,429 common shares in exchange for 9,014,758 warrants; exchange consummated Oct 10, 2025.
Owlet appoints Jonathan Harris as CEO; Workman becomes Executive Chair
Kurt Workman resigns as CEO, transitions to Executive Chair effective Oct 1, 2025.
Owlet settles derivative lawsuit over Smart Sock statements, agrees to governance reforms
Court preliminarily approved settlement of derivative action Vargas v. Workman on Sept 11, 2025.
Owlet exchanges warrants for 5.43M new shares; stockholder approval required
Exchange of up to 9,014,758 warrant shares for 5,426,429 new common shares; stockholder approval required at 2025 annual meeting.
Owlet swaps warrants for 5.4M new common shares; requires stockholder approval
Exchanges Series A warrants (7,215,737 shares) and Series B warrants (1,799,021 shares) for 5,426,429 new common shares.
Owlet Q2 revenue $26.1M (+26% YoY), raises FY2025 guidance; announces CEO transition
Q2 revenue $26.1M, up 25.9% YoY; gross margin 51.3%, up 180 bps.
Owlet amends credit facility; eases financial covenants and expands borrowing base
Minimum TTM EBITDA relaxed: $(3.9M) at Dec 2024, $(4.8M) at Mar 2025, rising to $6.5M by Dec 2026.
Owlet Q1 revenue $21.1M (+43% YoY); raises FY2025 revenue guidance to $91-95M
Q1 revenue $21.1M, up 43.1% YoY; gross margin 53.7%, up 930 bps to 53.7%.
Owlet Q4 revenue $20.5M, gross margin 53.5%; FY2024 rev up 45% to $78.1M; guides FY2025 rev $88-92M
Q4 revenue $20.5M (down 2% YoY but up 37% adjusting for Amazon partner shift); gross margin 53.5% (+650 bps).
Owlet Q3 revenue up 141% to $22.1M; adj. EBITDA positive $0.6M; raises FY2024 guidance
Revenue $22.1M (+141% YoY); gross margin 52.2% (up 1,590 bps).
Owlet amends bylaws to adopt universal proxy rules and enhance stockholder nomination procedures
Amendments address SEC universal proxy rules by requiring compliance with Rule 14a-19.
Owlet raises ~$11.6M via 3.14M share offering at $3.70; issues underwriter warrant
Gross proceeds ~$11.6M from sale of 3,135,136 shares of Class A common at $3.70 per share.
Owlet refinances SVB debt, enters new $15M ABL revolver and $15M WTI loan facility
Enters $15M asset-based revolving credit facility (increases to $20M after 1 yr); SOFR +7.5%-8.5%, matures Sept 2027.
Owlet preferred holders convert shares; market cap ~$54M, addressing NYSE compliance
15,721 Series A preferred shares converted into 2,291,686 Class A common shares.
Owlet stockholders elect directors, approve 400k share increase to incentive plan
Elected Laura J. Durr, Amy N. McCullough, Lior Susan as Class III directors with >8.7M votes each.
Owlet Q2 revenue up 58% to $20.7M, adjusted EBITDA turns positive at $0.1M
Revenue of $20.7M, up 58% YoY; gross margin 50%, up ~1,000 bps from 2023.
Owlet appoints Amanda Twede Crawford as CFO; Kate Scolnick departs; reaffirms 2024 goals
Amanda Twede Crawford promoted from VP FP&A to CFO effective July 9, 2024; Kate Scolnick to stay in advisory role through September 2024.
Owlet sets Aug 16, 2024 annual meeting; stockholder proposal deadline June 28, 2024
Board set August 16, 2024 as date for 2024 annual meeting of stockholders.
Owlet Q1 revenue $14.8M (+37% YoY); net income $3.3M vs loss $11.9M YoY
Gross margin 44.4%, up 570 bps YoY; adjusted EBITDA loss improved 46% to $3.1M.
Owlet Q4 revenue $21M, net loss down 65% YoY; FY23 gross margin up 810 bps
Q4 revenue ~$21.0M; gross margin 47.1%; net loss ~$6.9M vs $19.5M YoY.
Owlet raises $9.25M via Series B Convertible Preferred and warrants
Sold 9,250 Series B Convertible Preferred shares and warrants for 1,799,021 Class A common shares, aggregate $9.25M.
Gross proceeds $9M from sale of Series B convertible preferred and warrants; expected close Feb 28.
Owlet prelim Q4 revenue $21M (+75% YoY), net loss down 65%, adj EBITDA near breakeven
Q4 gross sales ~$32.9M, up 114% YoY; net revenue ~$21.0M, up 75% YoY.
Owlet Q3 2023 revenue $9.2M, net loss $5.6M; FDA clears Dream Sock OTC
Q3 revenue $9.2M, down 47% YoY due to shift to Amazon first-party seller; sell-in shifted to Q4.
Owlet receives FDA de novo clearance for Dream Sock as first OTC infant pulse oximeter
FDA-cleared Dream Sock monitors pulse rate and oxygen saturation for healthy infants 1-18 months, 6-30 lbs.
Owlet appoints Eclipse Investment Partner Marc Stoll to board, replacing Jayson Knafel
Director Jayson Knafel resigned Aug 11, 2023 to become CFO of an unaffiliated company; no disagreement with Owlet.
Owlet announces Q2 2023 results; press release text incomplete – no specific figures available
Filing states press release for Q2 2023 results furnished as Exhibit 99.1.
Owlet appoints Jonathan Harris as President and Chief Revenue Officer
Jonathan Harris appointed effective July 25, 2023; Kurt Workman remains CEO.
Owlet appoints Melissa Gonzales to board; brings women's health and consumer healthcare expertise
Melissa Gonzales appointed as Class I director effective July 18, 2023, term expiring at 2025 annual meeting.
Owlet announces NYSE acceptance of compliance plan; cure period extended 18 months
NYSE accepted Owlet's business plan to regain compliance with continued listing standards under Section 802.01B.
Reverse split reduces outstanding Class A common stock from ~118M to ~8.4M shares.
Owlet stockholders approve reverse stock split and Eclipse ownership proposal at 2023 annual meeting
Elected directors Jayson Knafel and Kurt Workman to Class II board seats through 2026.
Owlet receives FDA clearance for BabySat pulse-ox; NYSE commences warrant delisting
FDA cleared BabySat, first medical pulse-ox device with wire-free sock design; US launch expected later in 2023.
Owlet issues Q1 2023 earnings press release; financial details not available in filing excerpt
Press release dated May 11, 2023, reporting results for three months ended March 31, 2023.
Owlet receives NYSE delisting notice for low market cap and equity
NYSE notified Owlet on April 4, 2023, that its average market cap and stockholders' equity were both below $50 million (Section 802.01B).
Deferred principal payments from March 1, 2023 through August 1, 2023; repayments resume September 1, 2023 at $500k/month plus interest.
Owlet issues press release for Q4/FY2022 results; financial details unavailable in provided text
Owlet announced Q4 and FY2022 results via press release on March 15, 2023.
Owlet raises $30M via Series A convertible preferred and warrants; appoints new director
$30M gross proceeds from private placement of Series A convertible preferred stock and warrants.
FDA accepts Owlet's de novo submission for Health Notifications SaMD for heart rate and oxygen
FDA accepted for substantive review Owlet's de novo classification request for over-the-counter SaMD 'Health Notifications'.
Owlet receives NYSE non-compliance notice for stock price below $1.00
NYSE notified Owlet on Nov 29, 2022 that average closing price was below $1.00 for 30 consecutive trading days.
appointed Amanda Twede Crawford, the Company’s current Vice President, Financial Planning and Analysis, to serve as the Company’s Chief Financial Officer and principal financial officer and principal accounting officer, effective July 9, 2024
Ms. Scolnick, the Company’s Chief Financial Officer and principal financial officer and principal accounting officer, transitioned out of these positions effective July 9, 2024
On August 11, 2023, Jayson Knafel, a Class II director of Owlet, Inc. (the “Company”) and a member of the Compensation Committee of the Company’s Board of Directors (the “Board”), who served on the Board as a designee of Eclipse Ventures, LLC (“Eclipse”), notified the Company of his intention to resign from the Board, effective August 11, 2023.
On August 15, 2023, and effective as of that date, the Board appointed Marc F. Stoll, an Eclipse Designee, to serve on the Board as a Class II director of the Company, for a term expiring at the Company’s 2026 annual meeting of stockholders and until his successor has been elected and qualified or until his earlier death, resignation or removal.
On July 25, 2023, Owlet, Inc. (the “Company”) announced the appointment of Jonathan Harris as President and Chief Revenue Officer of the Company, effective July 25, 2023
appointed Melissa Gonzales to serve as a Class I director of the Board, effective July 18, 2023
On March 30, 2023, the Company’s Board of Directors appointed Kathryn R. Scolnick, the Company Chief Financial Officer and principal financial officer, to also serve as the Company’s principal accounting officer, effective with Mr. Yoo’s departure.
On March 29, 2023, Mr. Nathaniel Yoo, Senior Vice President and Chief Accounting Officer and principal accounting officer of the Company, tendered his resignation from the Company, effective March 31, 2023.
The Company appointed Jayson Knafel, an Eclipse designee, to serve as a member of the Board as a Class II Director, for a term expiring at the Company’s annual meeting of stockholders to be held in 2023 and until his respective successor has been elected and qualified or until his earlier death, resignation or removal, effective following the execution of the Stockholders Agreement.
The board of directors of Owlet, Inc. (the “Company”) appointed the Company’s co-founder and Chief Executive Officer, Kurt Workman, as President and Chief Executive Officer of the Company, effective September 1, 2022.
On August 11, 2022, the Company announced that Michael Abbott, President of the Company, intends to resign as President and as a member of the Company’s Board of Directors (the “Board”) effective September 1, 2022 (the “Separation Date”).
On March 28, 2022, Ken Suslow tendered his resignation as a Class II director of the Board of Directors (the “Board”) of Owlet, Inc. (the “Company”), and will step down from the Board and its Audit Committee, effective immediately.
Max materiality 0.80 · Median 0.65 · Most common event earnings